Literature DB >> 3965495

Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients.

N A Samaan, P N Schultz, T P Haynie, N G Ordonez.   

Abstract

Well differentiated thyroid carcinoma was diagnosed in 1,127 patients at The University of Texas M.D. Anderson Hospital and Tumor Institute at Houston from 1951 to 1981. Of those 1,127 patients, 101 had documented pulmonary metastasis. A retrospective analysis was conducted, and these patients were followed up until 1983. The primary tumors in these patients were histologically classified as papillary (67%), follicular (22%), or Hurthle cell (11%). The age at diagnosis ranged from 5-87 yr. Lung metastasis was diagnosed by both chest x-ray and positive uptake of 131I in 49 patients. Forty-two patients had positive chest x-ray results and negative 131I scans, and 10 patients had positive 131I scans and negative chest x-ray results. The patients were treated with radioactive iodine (76%), chemotherapy (9%), external radiotherapy (2%), or supportive care only (14%). Sixty-seven patients subsequently died of thyroid carcinoma. Our studies showed the following. 1) Patients who were younger than 40 yr of age at diagnosis had better prognosis (71% survival) compared with those over 40 yr of age (16% survival; P less than 0.01). 2) Uptake of radioactive iodine by lung metastasis is a favorable prognostic factor, especially in patients with negative radiological findings. Patients treated with radioactive iodine have a longer survival than those not treated with radioactive iodine (P less than 0.002). 3) The incidence of pulmonary metastasis is significantly less in patients who are treated by total thyroidectomy than in those treated with less than total thyroidectomy (P less than 0.03). 4) The incidence of pulmonary metastasis is lowest in patients with papillary carcinoma (9%), compared with that in patients with follicular (13%) or Hurthle cell (25%) carcinoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965495     DOI: 10.1210/jcem-60-2-376

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

Review 1.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

Review 2.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

4.  Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?

Authors:  H Chen; T L Nicol; M A Zeiger; W C Dooley; P W Ladenson; D S Cooper; M Ringel; S Parkerson; M Allo; R Udelsman
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

5.  Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study.

Authors:  H Scherübl; F Raue; R Ziegler
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

6.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

7.  Thyroid hormone-producing metastases in differentiated thyroid cancer.

Authors:  J L Gross; I Vasques Moraes
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

8.  Metastatic thyroid carcinoma of the adrenal gland.

Authors:  M E Girelli; D Casara; D Rubello; M Piccolo; A Piotto; M R Pelizzo; B Busnardo
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256

9.  Breast cancer brain metastases express the sodium iodide symporter.

Authors:  Corinne Renier; Hannes Vogel; Onyinye Offor; Chen Yao; Irene Wapnir
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

Review 10.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.